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The extended family of CD1d-
restricted NKT cells: sifting through a 
mixed bag of TCRs, antigens, and 
functions
Elodie Macho-Fernandez and Manfred Brigl*
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Natural killer T (NKT) cells comprise a family of specialized T cells that recognize lipid anti-
gens presented by CD1d. Based on their T cell receptor (TCR) usage and antigen specific-
ities, CD1d-restricted NKT cells have been divided into two main subsets: type I NKT cells 
that use a canonical invariant TCR α-chain and recognize α-galactosylceramide (α-GalCer), 
and type II NKT cells that use a more diverse αβ TCR repertoire and do not recognize 
α-GalCer. In addition, α-GalCer-reactive NKT cells that use non-canonical αβ TCRs and 
CD1d-restricted T cells that use γδ or δ/αβ TCRs have recently been identified, revealing 
further diversity among CD1d-restricted T cells. Importantly, in addition to their distinct 
antigen specificities, functional differences are beginning to emerge between the different 
members of the CD1d-restricted T cell family. In this review, while using type I NKT cells as 
comparison, we will focus on type II NKT cells and the other non-invariant CD1d-restricted 
T cell subsets, and discuss our current understanding of the antigens they recognize, the 
formation of stimulatory CD1d/antigen complexes, the modes of TCR-mediated antigen 
recognition, and the mechanisms and consequences of their activation that underlie 
their function in antimicrobial responses, anti-tumor immunity, and autoimmunity.
Keywords: CD1d, antigen presentation, lipid antigens, glycosphingolipids, phospholipids, inflammation, infection, 
cancer
introduction
Traditionally, the immune system has been separated into innate and adaptive immunity. However, 
in an unconventional way, innate T cells such as CD1d-restricted natural killer T (NKT) cells, MR1-
restricted mucosal-associated invariant T (MAIT) cells, γδ T cells, and some CD1a, b, c-restricted T 
cells share features of both innate and adaptive immune cells, allowing them to form a critical bridge 
between the two arms of the immune system (1–4). NKT cells recognize lipid antigens presented 
by the monomorphic MHC class-I-like molecule CD1d and are highly conserved in humans and 
mice. In response to a wide range of self- and foreign antigens, NKT cells are activated rapidly and 
exhibit both pro-inflammatory and immunoregulatory characteristics, resulting in either protective 
or harmful roles in numerous pathological states in mice and humans, including microbial infec-
tion, autoimmune disease, allergic disease, and cancer (5–10). Therefore, NKT cells represent an 
immunotherapeutic target with broad clinical potential. CD1d-restricted T cells can be divided into 
four main subsets based on their T cell receptor (TCR) usage and antigen specificities (Table 1). 
Type I (or invariant) NKT cells constitute the first and best characterized subset, and use an invariant 
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TCRα chain (Vα14-Jα18 in mice and Vα24-Jα18 in humans). In 
addition, there are CD1d-restricted T cells that use a more varied 
TCR repertoire, including Vα24− and Vα10+ NKT cells in mice 
and humans, respectively, diverse or type II NKT cells, as well as T 
cells expressing γδ or δ/αβ TCRs. In this review, while using type 
I NKT cells as comparison, we will focus on type II NKT cells and 
the other non-invariant CD1d-restricted T cell populations and 
discuss our emerging understanding of their TCR usage, antigen 
specificities, mode of antigen/CD1d recognition, innate-like 
mechanisms of activation, and their immunological functions.
The CD1d-Restricted T Cell Family
Type i NKT Cells
The discovery of the first CD1d-presented antigen, 
α-galactosylceramide (α-GalCer), by Kawano and colleagues 
in 1997 enabled several important steps forward in our under-
standing of NKT cell biology, particularly of type I or invariant 
NKT (iNKT) cells (11). Type I NKT cells express an invariant 
Vα14Jα18 TCR α-chain in mice and Vα24Jα18 in humans, 
paired with a limited repertoire of TCR β-chains (Vβ8, Vβ7, Vβ2 
in mice and exclusively Vβ11 in humans) (Table 1). Type I NKT 
cells are highly autoreactive even at steady state and display an 
activated/memory phenotype with high surface levels of the 
activation markers CD69, CD44, and CD122 (IL-2R β-chain) 
and low expression of CD62L, a marker expressed by naïve T 
cells that home to lymph nodes (12, 13). The use of mice that are 
deficient in CD1d (lack type I and type II NKT cells) or selec-
tively deficient in type I NKT cells (Jα18−/−), administration of 
α-GalCer to activate type I NKT cells in vivo, and the ability to 
track type I NKT cells with fluorescent CD1d/α-GalCer tetram-
ers has allowed the elucidation of many functions of type I NKT 
cells in  vivo. Type I NKT cells play critical roles in local and 
systemic immune responses and are essential for controlling 
TABLe 1 | Classification of CD1d-restricted T cells.
Type i NKT cells vα24− (h) and vα10+ (m)  
NKT cells
Type ii NKT cells γδ and δ/αβ T cells
TCR repertoire m: invariant (i)Vα14Jα18, Vβ8, Vβ7 or Vβ2 m: iVα10Jα50, Vβ8 m: diverse with oligoclonal  
Vα3.2-Jα9/Vβ8 and Vα8/Vβ8
m: Vδ4+
h: iVα24Jα18, Vβ11 h: limited α chains (Vα10, Vα2 
or Vα3), Vβ11
h: diverse? h: Vδ1+, Vδ3+
α-GalCer reactivity all all no some
Sulfatide reactivity no no some some
Other antigens Microbial α-GSL, α-GDAG Microbial α-GSL Mammalian and microbial 
phospholipids (PG, DPG, PI)
Mammalian and pollen 
phospholipids (PE, PC, DPG)
Mammalian β-GSL, phospholipids, 
lysophospholipids, plasmalogens
Mammalian β-GSL and 
β-GlcSph
Mammalian lysophospholipids 
(LPC, LSM, LPE, β-GlcSph)
Function NKT1 (IFN-γ, IL-2) TH1-like (IFN-γ) TH1-like (IFN-γ, IL-2) TH1-like (IFN-γ)
NKT2 (IL-4, IL-9, IL-10, IL-13) TH2-like (IL-4, IL-13) TH2-like (IL-4, IL-10, IL-13) TH2-like (IL-4)
NKT17 (IL-17A, IL-21, IL-22) TH17-like (IL-17) TH17-like (IL-17)
NKTFH-like (IL-5, IL-6, IL-10, IL-17) Cytotoxicity (perforin, granzyme)
Cytotoxicity (perforin, granzyme) TFH-like (IL-5, IL-6, IL-10, IL-17)
Phenotype Activated/memory Activated/memory some naïve? Activated/memory some naïve? Activated/memory
α-GalCer, α-galacotsylceramide; α-GSL, α-glycosphingolipid; α-GDAG, α-glyco(Gal/Glc)diacylglycerol; β-GlcSph,β-glucosylsphingosine; DPG, diphosphatidylglycerol; h, human; 
LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LSM, lysosphingomyelin; m, mouse; PG, phosphatidylglycerol; NKT, natural killer T cell; TCR, T cell receptor.
tumor development and antimicrobial immune responses. They 
can also exert detrimental effects in the pathogenesis of autoim-
mune and allergic disorders. The biology of type I NKT cells 
has been extensively covered in several excellent recent reviews 
(2, 3, 14–16), including their roles in microbial infections (2, 7, 
17–20), autoimmunity and inflammation (9, 21, 22), and tumor 
immunity (23). This broad range of type I NKT cell functions 
relies on their rapid secretion of copious amounts of various 
cytokines, including IFN-γ, IL-2, IL-4, IL-9, IL-10, IL-13, 
IL-17, IL-21, and GM-CSF (24–26), and their interactions with 
other immune cells (2, 16). Based on the differential expres-
sion of cytokines, transcription factors and surface markers, 
several functionally distinct type I NKT cell subsets have been 
described in humans and mice (Table 1). Human type I NKT 
cells expressing CD4 produce Th2-type cytokines whereas both 
CD4+ and CD4− subsets can generate Th1-type cytokines and 
secrete cytotoxic molecules such as perforin and granzyme (24, 
27). In C57BL/6 mice, Th1-like type I NKT cells (also referred 
to as NKT1 cells) represent the majority of type I NKT cells in 
liver and spleen, are characterized by the Th1-associated tran-
scription factor T-bet, mostly express NK1.1 and IL-12 receptor 
(IL-12R) and their pronounced production of IFN-γ is critical 
for their function during various immune responses, including 
anti-tumor immunity (24, 28, 29). Th2-like type I NKT cells 
(NKT2 cells) are the most abundant type I NKT cell subset in 
BALB/c mice and are enriched in lung and intestine of C57BL/6 
mice. NKT2 cells have been reported to play an important role 
in Th2-mediated diseases through the secretion of IL-4, IL-9, 
IL-10, and IL-13 (30, 31). Th17-like type I NKT cells (NKT17 
cells) are primarily found in lung, skin and peripheral lymph 
nodes, produce IL-17A and IL-22 (26, 32, 33), and express 
the retinoic acid receptor-related orphan receptor γt (RORγt) 
transcription factor (34). Finally, a small number of type I NKT 
cells with developmental, phenotypical, and functional features 
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of follicular helper (35) T cells secrete IL-21, support the forma-
tion of germinal centers (36–38) and require the transcription 
factor Bcl-6 for their development (36). Despite their varied 
functional differentiation, most type I NKT cell subsets express 
the transcription factors PLZF, which is fundamental for their 
development, and GATA3 (39). However, instead of PLZF, a 
distinct type I NKT cell population, newly referred to as NKT10 
cells, express the transcription factor E4BP4 which confers their 
regulatory properties (40, 41). Thus, the remarkable functional 
versatility of type I NKT cells during various immune responses 
can at least in part be explained by the existence of functionally 
distinct subsets, while organ-specific functions and plasticity of 
type I NKT cell subsets have not been adequately investigated.
α-GalCer-Reactive vα24− and vα10+ NKT Cells
Recognition of α-GalCer by type I NKT cells was thought to 
be highly correlated with expression of the invariant Vα14-Jα18 
or Vα24-Jα18 TCR α-chains in mice and humans, respectively. 
However, α-GalCer-reactive, CD1d-restricted NKT cells that 
use different TCR α-chains have subsequently been described in 
both mice and humans. In humans, one study using α-GalCer-
loaded CD1d tetramers found Vα24-negative T cell populations 
expressing Vα10, Vα2, or Vα3 joined to Jα18 and paired with 
Vβ11 (42) whereas another study found a diversity of Vα24− 
Jα18−/Vβ11− TCRs that stained with α-GalCer/CD1d tetramers 
(Table 1) (42–44). Despite their equivalent reactivity to α-GalCer 
or bacterial α-linked glycosphingolipids (GSLs), Vα24-negative 
subset displayed preferential antigen specificities for α-GlcCer 
(42). Surprisingly, a Vα24−/CD1d-α-GalCer+ population was 
found to predominantly display a naïve phenotype and low or 
intermediate expression level of PLZF (45). So far, data regard-
ing the function of these NKT cells in humans are limited.
Similarly, in mice, CD1d-restricted NKT cells that recog-
nize α-GalCer but do not use the canonical Vα14-Jα18 TCR 
α-chain have also been described, and predominantly express 
a semi-invariant Vα10-Jα50 TCR α-chain paired with a Vβ8+ 
TCR β-chain (Vβ8.1/0.2 or Vβ8.3). Vα10+ NKT cells have 
been identified in thymus, spleen, and liver of Jα18−/− mice by 
CD1d-α-GalCer tetramer staining, and displayed a CD44high 
CD69int pre-activated phenotype, similar to type I NKT cells. 
Like other NKT cell populations, their development required 
expression of CD1d. In addition to α-GalCer, Vα10+ NKT cells 
preferentially recognize other glucose-based glycolipids such 
as α-GlcCer, GSL-1 from Sphingomonas or α-GlcA-DAG from 
Mycobacterium smegmatis, and in response to stimulation with 
these glycolipids produce large amounts of cytokines includ-
ing IFN-γ, IL-4, IL-13, and IL-17 (46). Thus, recognition of 
CD1d/α-GalCer complexes by NKT cells in humans and mice 
is not uniformly restricted to the use of Vα24-Jα18/Vβ11 or 
Vα14-Jα18 TCRs, respectively, but can be mediated by a range 
of Vα and Vβ domains, highlighting the variation in antigen 
recognition among CD1d-restricted α-GalCer-reactive TCRs. 
Furthermore, the different antigen specificities of some of these 
non-canonical α-GalCer-reactive NKT cells may correlate with 
distinct functional capabilities, and it remains to be explored if 
this subset harbors NKT cells that can be expanded in vivo and 
form memory responses.
Type ii NKT Cells
CD1d-restricted T cells that do not express the Vα14-Jα18 rear-
rangement and do not recognize α-GalCer were first described 
in MHC II-deficient mice among the remaining CD4+ T cells 
(47). From then called diverse NKT (dNKT), type II NKT, or 
variant NKT (vNKT) cells, this NKT cell population, found in 
both mice and humans, exhibits a more heterogeneous TCR 
repertoire (Table  1). For example in mice, the type II NKT 
cells that have been described use Vα1, Vα3, Vα8, or Vα11 
TCR α-chains paired with Vβ8 or Vβ3 TCR β-chains, or Vα4 
paired with Vβ5 or Vβ11, and appear to contain oligoclonal 
Vα3.2-Jα9/Vβ8 and Vα8/Vβ8 TCR families (48–50). Currently, 
no direct and specific tools exist to identify the entire type II 
NKT cell population in vivo, but different approaches have been 
developed to study these cells in mice. The first is to compare 
the immune responses between Jα18−/− mice (lacking only type 
I NKT cells) and CD1d−/− mice (lacking both type I and type II 
NKT cells). It should be noted that Jα18−/− mice exhibit lower 
TCR repertoire diversity due to deficits in rearrangements of 
several Jα segments (51). This raises the possibility that defects 
described in Jα18−/− mice are not solely due to type I NKT cell 
deficiency and a more specific type I NKT cell-deficient mouse 
model is needed. The second tool used to study type II NKT cell 
function is 24αβ TCR transgenic mice that were generated by 
overexpressing the Vα3.2/Vβ9 TCR from the type II NKT cell 
hybridoma VIII24 (52). A third approach is the use of Jα18-
deficient IL-4 GFP (Jα18−/− 4get) reporter mice. This model is 
based on the finding that some type II NKT cells spontaneously 
express IL-4 mRNA transcripts, similar to type I NKT cells (53, 
54). However, this approach does not identify all type II NKT 
cells since, for example, GFP+ type II NKT cells from Jα18−/− 4get 
mice do not respond to sulfatide, an antigen that is recognized by 
a significant number of type II NKT cells. The fourth approach 
to identify type II NKT cells is the use of lipid antigen-loaded 
CD1d tetramer reagents, similar to the use of α-GalCer/CD1d 
tetramers that are used to detect type I NKT cells. The discovery of 
sulfatide as a potent type II NKT cell ligand led to the generation 
of sulfatide-loaded CD1d tetramers and revealed an oligoclonal 
TCR repertoire among sulfatide-specific type II NKT cells with 
predominant use of Vα3/Vα1-Jα7/Jα9 and Vβ8.1/Vβ3.1-Jβ2.7 
genes (50, 55, 56). However, sulfatide/CD1d tetramers appear to 
be more difficult to use compared to α-GalCer/CD1d tetramers, 
likely due to difficulties in loading the antigen and/or greater 
instability of sulfatide/CD1d complexes and, moreover, not all 
type II NKT cells recognize sulfatide (50, 54). Similar to sul-
fatide, β-glucosylceramide (β-GlcCer)- or glucosylsphingosine 
β-GlcSph-loaded CD1d tetramers stained a subset of human 
and mouse type II NKT cells (57). Furthermore, the recent 
discovery of several microbial antigens recognized by different 
type II NKT hybridomas enables the design of antigen-loaded 
CD1d tetramers that are likely to be useful to characterize type 
II NKT cells in vivo (58, 59). Another approach to study type 
II NKT cells is the use of dNKT hybridomas that were initially 
identified by their recognition of CD1d-expressing APC and 
their use of TCR α-chains different from Vα14-Jα18 (47–49, 
60, 61). These dNKT hybridomas were used to characterize the 
TCRs expressed by type II NKT cells and continue to be used to 
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identify self- and microbial lipid antigens that are recognized by 
type II NKT cells.
Using the approaches described above, many type II dNKT 
cells appear to share phenotypic and functional features with type 
I NKT cells such as high autoreactivity (62), PLZF- and SAP-
dependent thymic development (54, 63), constitutive expression 
of IL-4 mRNA (54), and the ability to secrete a wide range of 
cytokines rapidly after stimulation, including IFN-γ, IL-2, IL-4, 
IL-10, IL-17, GM-CSF, and cytolytic mediators such as perforin 
(54, 63). Furthermore, many type II NKT cells have a CD44high 
CD69+ CD122+ activated/memory phenotype, whereas CD62L 
is more or less expressed dependent on which transgenic mouse 
model is used, and can be divided into different subsets depend-
ing on CD4 and NK1.1 expressions (54, 63–65). However, several 
studies suggest that type II NKT cells exist that are phenotypically 
and functionally distinct from type I NKT cells. For example, 
most of the T cells stained with sulfatide/CD1d tetramers in 
C57BL/6 mice did not express the early activation marker CD69 
(50). Moreover, in 24αβ TCR transgenic mice on the non-obese 
diabetic (NOD) background, the majority of DN 24αβ NKT 
cells were CD44int, CD45RBhigh, CD62Lhigh, CD69−/low, similar to 
conventional T cells, whereas the majority of CD4+ 24αβ NKT 
cells exhibited the typical type I NKT CD44high, CD45RBlow, 
CD62Llow, CD69high activated/memory phenotype (66). In addi-
tion, in both humans and mice, type II NKT-TFH populations 
have recently been described that recognized β-GlcCer or 
β-GlcSph (57). The human type II NKT-TFH population utilized 
Vα24−/Vβ11− TCRs with diverse Vβ chains and displayed a 
naïve CD45RA+, CD45RO−, CD62high, CD69−/low phenotype. The 
majority of these cells expressed a TFH-like phenotype in mice and 
humans (CXCR5+, PD-1high, ICOShigh, Bcl6high, FoxP3−, IL-21+) at 
steady state and mainly secreted IL-5, IL-6, IL-10, and IL-17 fol-
lowing activation. Their TFH properties were associated with the 
induction of GC B cells and lipid-specific antibodies in vivo in a 
CD1d-dependent manner.
In humans, CD1d-restricted type II NKT cells appear to be 
much more frequent than type I NKT cells. In human bone mar-
row, approximately 25% of CD3+ T cells expressed CD161 and 
half of the CD161+CD3+ cells recognized CD1d. Interestingly, 
the majority of these CD1d-restricted T cells used Vα24−/Vβ11− 
TCRs (67). In PBMC of healthy individuals, approximately 0.5% 
of CD3+ lymphocytes stained with β-GlcCer/CD1d tetramers, 
similar to numbers in Gaucher’s disease patients, whereas 
1–2% of CD3+ lymphocytes in these patients stained positive 
with β-GlcSph/CD1d tetramers, compared to 0.2% in healthy 
individuals (57). In myeloma patients, lysophosphatidylcholine 
(LPC)-loaded CD1d dimers stained on average 0.6% of T cells 
in PBMC, several fold higher than type I NKT cell numbers 
determined with α-GalCer-loaded CD1d dimers (68), whereas in 
healthy controls, both LPC- and α-GalCer-loaded CD1d dimers 
stained approximately 0.05% of PBMC.
Thus, type II NKT cells can be distinguished from type I 
NKT cells by their use of more diverse TCRs and their distinct 
antigen specificities. Many type II NKT cells are phenotypically 
and functionally similar to type I NKT cells, however, some 
type II NKT cells appear to have a naïve T cell phenotype and 
further studies are required to test if these cells are capable to 
form antigen-specific memory responses. In addition, similar to 
type I NKT cells, type II NKT cells may also harbor function-
ally distinct subsets, and it will be important to determine to 
what extent functional differentiation correlates with antigen 
specificities.
CD1d-Restricted γδ and δ/αβ T Cells
In addition to the use of αβ TCRs, CD1d-restricted T cells 
expressing γδ TCRs have recently been described in both mice 
and humans (Table 1). According to their Vδ-chain expression, 
human γδ T cells can be divided into two major populations: 
Vδ2+ and “non-Vδ2” subsets, the latter comprise Vδ1+ γδ T cells 
and the less prevalent Vδ3+ γδ T cells (69, 70). Vδ1+ γδ T cells are 
mainly tissue-resident and are found in the skin and at mucosal 
surfaces, whereas Vδ2+ γδ T cells are predominant in human 
blood. Compared with αβ T cells, the types of antigens recognized 
by γδ T cells and the role and function of antigen presentation 
in γδ TCR recognition are much less clear. Interestingly, some 
γδ T cells have recently been found to directly recognize CD1d-
presented lipid antigens (71). Indeed, Spinazzo and colleagues 
showed that only γδ T cells, but not αβ T cells, from peripheral 
blood and nasal mucosa of cypress pollen-sensitive subjects 
were activated in a CD1d-dependent manner by phospholipids 
extracted from pollen grains (72–74). Up to now thought of as 
type I NKT cell-specific ligands, α-GalCer and some of its deriva-
tives including OCH were recognized by a subset of circulating 
human Vδ1+ γδ T cells (75). Similarly, sulfatide-reactive CD1d-
restricted Vδ1+ γδ T cells were found in human blood and among 
gut T cells (76, 77). In addition, Vδ3+ γδ T cells found in the liver 
of patients with leukemia or chronic viral infection recognized 
CD1d molecules and killed CD1d+ cells (78). In mice, develop-
ment of myocarditis following infection with coxsackievirus B3 
(CVB3) relied on CD1d up-regulation and CD1d-dependent 
activation of Vγ4+ γδ T cells (79). Furthermore, α-GalCer reac-
tive, CD1d-restricted T cells using TCRs in which the Vδ1 gene is 
fused to Jα and Cα domains that are paired with an array of TCR 
β-chains to form a δ/αβ TCR have recently been described (80). 
Thus, lipid-specific γδ and δ/αβ TCRs expand the TCR diversity 
among CD1d-restricted T cells. Understanding the full range of 
antigens that are recognized by CD1d-restricted T cells that use 
TCR γ/δ genes, the extent of permissive TCR diversity and the 
numbers of these cells under physiologic conditions and during 
infection and other pathologies constitute important areas for 
future exploration.
Mechanisms of CD1d-Restricted  
T Cell Activation
In contrast to the high degree of TCR diversity and antigen speci-
ficity of adaptive MHC-restricted T cells, CD1d-restricted T cells 
utilize a more restricted TCR repertoire and recognize antigens 
presented by a monomorphic antigen-presenting molecule. Yet, 
these cells are able to respond to highly diverse infectious agents 
and become activated in a variety of non-infectious pathological 
conditions. Recent progress has started to shed light on how the 
self- and exogenous lipid antigens that are presented by CD1d, 
the molecular underpinnings of TCR-mediated recognition of 
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lipid/CD1d complexes, the antigen-presenting pathways that 
result in formation of stimulatory lipid/CD1d complexes, and 
the non-TCR signals all contribute to the activation of type 
II NKT cells and other non-invariant CD1d-restricted T cell 
populations.
CD1d-Presented Ligands
α-galactosylceramide and numerous related derivatives have 
helped to define the range of antigen specificity among type I 
NKT cells and provide powerful agents for their pharmacologic 
stimulation with various functional outcomes (Figure  1). 
Furthermore, several α-linked GSLs and diacylglycerols that 
stimulate type I NKT cells have been isolated from various 
microbes, confirming that α-linked GSLs are indeed important 
natural antigens for type I NKT cells. In addition, an intensive 
search for the self-antigens that are critical for type I NKT cell 
development has revealed several candidates, including iGb3, 
β- and α-linked GSLs, and various phospholipids. All of these 
antigens have been the topic of excellent recent reviews and will 
not be discussed in detail here (81–84). Similarly, a number of 
endogenous and exogenous glycerol- or ceramide-based lipid 
antigens that stimulate non-invariant CD1d-restricted T cells 
have been identified, but significant differences in antigen 
specificity exist between the various CD1d-restricted T cell 
subsets as a result of their varied TCR usage. For example, type 
II NKT cells display specificities for antigens that are not typi-
cally considered to be agonists for type I NKT cells, but some 
overlap in antigen specificity between these two NKT cell sub-
sets is becoming apparent. In contrast, only subtle differences in 
antigen specificity have been observed between type I NKT cells 
and the non-canonical Vα24− NKT cells and Vα10+ in humans 
and mice, respectively. Interestingly, CD1d-restricted T cells 
with γ/δ TCRs have been identified that recognize α-GalCer or 
sulfatide, antigens that were thought to be specific for type I and 
type II NKT cells, respectively. Thus, antigen specificity alone is 
not a reliable criterion to define CD1d-restricted T cell subsets 
(Table 1; Figure 2).
Self-Ligands
Type II NKT cells were originally identified based on their 
autoreactivity to CD1d-expressing cells and subsequently indi-
vidual stimulatory self-lipid antigens were identified. In addi-
tion, numerous studies have now demonstrated the activation of 
non-invariant CD1d-restricted T cells in diseases where foreign 
lipids are not present, such as autoimmunity, cancer, viral infec-
tion, or in response to toll-like receptor agonists, suggesting 
that the recognition of self-lipids is critical for their peripheral 
activation.
Sulfatide (SO3-3Galβ1Cer) is a self-GSL recognized by a 
subset of type II NKT cells that predominantly express Vα3/Vα1 
and Vβ8.1/Vβ3.1 TCRs (Figure 1) (50, 55). Native sulfatide is a 
mixture of multiple sulfatide isoforms with different lengths and 
saturation of their fatty acid chains, and is found in many organs 
(brain, kidney, pancreatic β-cells) and tumor cells. A major com-
ponent of the myelin sheets of the central nervous system, the 
mono-unsaturated C24:1 sulfatide isoform activates XV19 type 
II NKT cells in a CD1d-dependant manner, unlike its saturated 
(C24:0) or shortened (C18:1) isoforms. Although found in the 
nervous system in only minor quantities, the lysosulfatide (LSF) 
that lacks the entire fatty acid chain, is the most potent sulfa-
tide isoform described (85). However, the XV19 type II NKT 
hybridoma exhibits high autoreactivity toward splenocytes from 
CST−/− mice that lack cerebroside sulfotransferase and therefore 
cannot generate sulfatide, and sulfatide-reactive NKT cells were 
still detected in CST−/− mice (55), indicating that sulfatide is 
not required for type II NKT cell development. Administration 
of sulfatide to mice has widely been used to study the function 
of sulfatide-specific type II NKT cells in  vivo. In humans, the 
majority of T cells in PBMC that stained with sulfatide-loaded 
CD1d tetramers were γδ T cells that use a semi-invariant Vδ1+ 
γδ TCR (76).
Another β-linked GSL, β-glucosylceramide (β-GlcCer), has 
recently been shown to activate type I and type II NKT cells 
(Figure  1). Stimulation of APC by diverse TLR agonists can 
modify the GSL biosynthesis pathway by enhancing the expres-
sion of several glycosyltransferases and, as a consequence, the 
accumulation of endogenous GSL, including β-GlcCer, that are 
then presented by CD1d (86, 87). However, two recent studies 
have questioned the role of β-GlcCer in the activation of type 
I NKT cells. The studies attributed the stimulatory activity of 
synthetic or mammalian β-GlcCer to co-purified α-GlcCer and 
suggest that mammalian immune cells produce constitutively 
small quantities of stimulatory α-glycosylceramides under con-
trol of catabolic enzymes of the ceramide and glycolipid pathway 
(88, 89). For type II NKT cells, the β-GlcCer-22:0 isoform and 
its deacylated product, glucosylsphingosine or β-GlcSph, have 
been shown to activate type II NKT subsets in humans and mice 
and CD1d tetramers loaded with these antigens can be used to 
stain these cells (57). In another example of induced self-lipid-
mediated activation, Zhao and co-workers showed that type 
II NKT cells in the Jα18-deficient IL-4 reporter mouse were 
activated in response to CpG ODN, a potent synthetic agonist of 
TLR9, which mimics a hallmark of microbial DNA (54). Similar 
to what has been observed for type I NKT cells (86), type II NKT 
cell activation by CpG ODN resulted in production of IFN-γ but 
not IL-4 or IL-13, and was partially CD1d-dependent. Type II 
NKT cells isolated from Jα18-deficient IL-4 reporter mice rec-
ognized β-GlcCer but not sulfatide or phospholipids. However, 
the lipids responsible for the activation of type II NKT cells fol-
lowing CpG ODN stimulation were not identified. Several type II 
NKT hybridomas (i.e., XV19, VIII24, VII57) were unresponsive 
to α-glycosylceramides such as α-GclCer (90) and autoreactivity 
of the XV19 type II NKT cell hybridoma persisted with use of 
β-GlcCer- or GSL-deficient cell lines, suggesting that glycolipids 
are not the only self-lipids responsible for the autoreactivity of 
type II NKT cells (91).
Mammalian phospholipids are a major component of cell 
membranes and have been identified as natural antigens that 
are recognized by CD1d-restricted NKT cells. Mouse CD1d-
restricted type I and type II NKT cell hybridomas exhibit 
distinct but overlapping antigen recognition specificities, 
particularly in response to phosphatidylinositol (PI), phos-
phatidylethanolamine (PE), and phosphatidylglycerol (PG) 
(Figure  1) (62). Mammalian phospholipids differ from their 
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microbial counterparts in the fatty acyl chain composition or 
the position of the fatty acyl molecules at the sn-1 and sn-2 posi-
tions of the glycerol backbone. Such modifications of the lipid 
tails can considerably impact type I NKT cell activation (92). 
Surprisingly, C16:0/18:1 PG isolated from murine skin, bovine 
DPG mainly composed of (C18:2/C:18:2)2 species and their 
respective synthetic version have high potency to activate the 
14S.10 type II NKT cell hybridoma in a CD1d-dependent man-
ner (58), suggesting that both self- and microbial phospholipids 
can be recognized by these T cells.
Lysophospholipids are produced after phospholipid 
hydrolysis by a phospholipase and act as lipid messengers in 
many physiological processes. These lipids are found in high 
concentration at inflammatory sites, suggesting a role in the 
etiology of disorders such as autoimmune diseases, obesity, 
atherosclerosis, and cancer. Markedly up-regulated in myeloma 
patients, LPC species were recognized by human type I NKT 
cell clones (93) and Vα24−/Vβ11− type II NKT cells (Figure 1) 
(68). Chang et al. also reported that human LPC-reactive type 
II NKT cells predominantly secreted IL-13 in response to 
LPC, suggesting an immunosuppressive function of these cells 
(68). LPC isoforms C18:0 and C16:0 were the most potent to 
activate sulfatide-reactive type II NKT cells compared to the 
C24:0 isoform (94). Notably, LPC is not recognized by murine 
type II NKT cells. Similar to LPC, lysosphingomyelin (LSM), 
which displays the same head group, choline, activated both 
type I and XV19 type II NKT cells (93, 94). Recently, Zeissig 
and co-workers showed that lysophosphatidylethanolamine 
(LPE), which accumulated during hepatitis B virus (HBV) 
infection, activated type II NKT cells from Jα18-deficient IL-4 
reporter mice but not type I NKT cells (53). This activation 
could be induced by different LPE isoforms, including C16:0, 
C18:0, and C18:1. Thus, activation of CD1d-restricted T cells 
in inflammatory contexts where exogenous microbial lipid 
antigens are not available can result from recognition of induc-
ible self-lipids.
Thus, several self-lipids are recognized by subsets of type II 
NKT cells and recognition of these lipids is important for type 
II NKT cell function. Indeed, during microbial infection and 
non-infectious inflammatory conditions, up-regulation and pres-
entation of self-lipids or stimulatory lyso forms converts innate 
danger signals into activation of type II NKT cells.
FiGURe 1 | Antigens recognized by CD1d-restricted T cells. Shown are 
the structures of lipid antigens for type I and/or type II NKT cells: the 
prototypical type I NKT cell glycolipid α-galactosylceramide (α-GalCer); the 
lipid self-antigen sulfatide (type II NKT cells); the mammalian 
phosphatidylglycerol (PG; type I and type II NKT cells) and its microbial 
counterparts from Corynebacterium glutamicum (Cg) or Mycobacterium 
tuberculosis (Mtb) (type II NKT cells); the mammalian diphosphatidylglycerol 
(DPG or cardiolipin) whose Mtb counterpart shares the same alkyl chains as 
Mtb PG (Type II NKT cells); lysophosphotidylethanolamine (lysoPE; type I and 
type II NKT cells), lysophasphatidylcholine (LysoPC; type I and type II NKT 
cells), and phenyl 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonate (PPBF, 
type II NKT cells).
FiGURe 2 | Antigen specificity of CD1d-restricted T cells. Type I NKT cells, Vα24− (human) and Vα10+ (mouse) NKT cells, type II NKT cells, and CD1d-
restricted γδ and δ/αβ T cells have distinct and partially overlapping antigen specificities. h, human; m: mouse; Ms, Mycobacterium smegmatis.
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microbial counterparts in the fatty acyl chain composition or 
the position of the fatty acyl molecules at the sn-1 and sn-2 posi-
tions of the glycerol backbone. Such modifications of the lipid 
tails can considerably impact type I NKT cell activation (92). 
Surprisingly, C16:0/18:1 PG isolated from murine skin, bovine 
DPG mainly composed of (C18:2/C:18:2)2 species and their 
respective synthetic version have high potency to activate the 
14S.10 type II NKT cell hybridoma in a CD1d-dependent man-
ner (58), suggesting that both self- and microbial phospholipids 
can be recognized by these T cells.
Lysophospholipids are produced after phospholipid 
hydrolysis by a phospholipase and act as lipid messengers in 
many physiological processes. These lipids are found in high 
concentration at inflammatory sites, suggesting a role in the 
etiology of disorders such as autoimmune diseases, obesity, 
atherosclerosis, and cancer. Markedly up-regulated in myeloma 
patients, LPC species were recognized by human type I NKT 
cell clones (93) and Vα24−/Vβ11− type II NKT cells (Figure 1) 
(68). Chang et al. also reported that human LPC-reactive type 
II NKT cells predominantly secreted IL-13 in response to 
LPC, suggesting an immunosuppressive function of these cells 
(68). LPC isoforms C18:0 and C16:0 were the most potent to 
activate sulfatide-reactive type II NKT cells compared to the 
C24:0 isoform (94). Notably, LPC is not recognized by murine 
type II NKT cells. Similar to LPC, lysosphingomyelin (LSM), 
which displays the same head group, choline, activated both 
type I and XV19 type II NKT cells (93, 94). Recently, Zeissig 
and co-workers showed that lysophosphatidylethanolamine 
(LPE), which accumulated during hepatitis B virus (HBV) 
infection, activated type II NKT cells from Jα18-deficient IL-4 
reporter mice but not type I NKT cells (53). This activation 
could be induced by different LPE isoforms, including C16:0, 
C18:0, and C18:1. Thus, activation of CD1d-restricted T cells 
in inflammatory contexts where exogenous microbial lipid 
antigens are not available can result from recognition of induc-
ible self-lipids.
Thus, several self-lipids are recognized by subsets of type II 
NKT cells and recognition of these lipids is important for type 
II NKT cell function. Indeed, during microbial infection and 
non-infectious inflammatory conditions, up-regulation and pres-
entation of self-lipids or stimulatory lyso forms converts innate 
danger signals into activation of type II NKT cells.
FiGURe 1 | Antigens recognized by CD1d-restricted T cells. Shown are 
the structures of lipid antigens for type I and/or type II NKT cells: the 
prototypical type I NKT cell glycolipid α-galactosylceramide (α-GalCer); the 
lipid self-antigen sulfatide (type II NKT cells); the mammalian 
phosphatidylglycerol (PG; type I and type II NKT cells) and its microbial 
counterparts from Corynebacterium glutamicum (Cg) or Mycobacterium 
tuberculosis (Mtb) (type II NKT cells); the mammalian diphosphatidylglycerol 
(DPG or cardiolipin) whose Mtb counterpart shares the same alkyl chains as 
Mtb PG (Type II NKT cells); lysophosphotidylethanolamine (lysoPE; type I and 
type II NKT cells), lysophasphatidylcholine (LysoPC; type I and type II NKT 
cells), and phenyl 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonate (PPBF, 
type II NKT cells).
Microbial and Other Exogenous Ligands
Until recently, no microbial antigen had been identified that 
could be directly recognized by non-iNKT cells. Based on the 
ability of human CD1b molecules to present lipid antigens from 
Mycobacterium tuberculosis (Mtb) to diverse CD1b-restricted T 
cells (7) and due to the similarities between CD1b and CD1d 
intracellular trafficking and localization in humans (95), we 
investigated Mtb lipids for antigens that may be recognized by 
type II NKT cells. Purification, isolation and structural analysis 
of Mtb polar lipids revealed PG species with different acyl chain 
combinations (including C19:0/C16:0, C19:0/C16:1, C18:1/
C16:0, and C18:1/C16:1) to stimulate several type II NKT cell 
hybridomas (14S.6, 14S.10, TBA7, VII68, and XV19) in a CD1d-
dependent manner (Figure 1) (93). Moreover, PG, diphosphati-
dylglycerol (DPG or cardiolipin) and PI from Corynebacterium 
glutamicum (Cg), with C18:1/C16:0, (C18:1/C16:1)2, and C18:1/
C16:0 fatty acid composition, respectively, also activated type II 
NKT cells, in particular 14S.6, 14S.10, and TBA7 hybridoma cells. 
In addition, Mtb and Cg apolar lipids activated type II NKT cell 
clones in a CD1d-dependent manner, but specific stimulatory 
lipid species have not yet been identified from this lipid fraction. 
Similarly, Wolf and colleagues recently demonstrated that PG and 
DPG isolated from Listeria monocytogenes (Lm) were also potent 
ligands for type II NKT clones (TBA7 and 14S.10 especially) (59). 
Interestingly, whereas in both studies neither PG nor DPG from 
Mtb, Cg, and Lm succeeded in activating type I NKT cell hybri-
domas, DPG can be recognized by a subset of CD1d-restricted 
γδ T cells. Indeed, hepatic and splenic γδ T cells secreted IFN-γ 
and RANTES (CCL5) in response to DPG in a CD1d-dependent 
manner (74).
Phospholipids are also found in plant, especially in pollen, 
which are an important source of environmental allergens. 
Extracted from cypress grains, phospholipids, as PC in par-
ticular, stimulated non-Vα24 NKT and γδ T cells from cypress 
pollen-sensitive subjects in a CD1d-restricted fashion (72, 73, 
96). However, the structure of the acyl chain combination of the 
stimulatory PC from pollen has not been defined. Interestingly, 
non-lipidic small molecules can also be associated with CD1d pro-
teins with low affinity. These sulfur-containing molecules, includ-
ing phenyl 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonate 
(PPBF) and structurally related compounds (Figure 1), activated 
human non-Vα24− CD1d-restricted T cells that expressed a Vα2/
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Vβ21 TCR (97). Thus, in addition to the prominent recognition 
of self-lipid antigens, non-invariant CD1d-restricted T cells also 
recognize a range of microbial and exogenous lipids presented 
by CD1d.
CD1d/Antigen Recognition
Considering the differences in TCR usage and antigen spe-
cificities among the different CD1d-restricted T cell populations, 
unraveling the molecular mechanisms by which their TCRs 
recognize CD1d/antigen complexes is central to understanding 
their functions. Indeed, recent structural analyses have brought 
to light key differences in antigen/CD1d recognition by the TCRs 
of type I NKT cells, Vα24−/Vα10+ NKT cells, type II NKT cells, 
and γδ T cells.
The invariant type I NKT cell TCR docks over the F′ pocket 
of CD1d in an orthogonal conformation (Figures 3A,B) (98, 99). 
Only the α-chain, via the complementary-determining region 
1α (CDR1α) and CDR3α, is in contact with the head group of 
α-linked glycolipids such as α-GalCer, and thus has an important 
role in specificity for, and recognition of, glycolipids. CDR3β and 
CDR2β loops stabilize the complex by interacting with the CD1d 
molecule. Variations in TCR β-chain usage cause subtle structural 
modifications in the conformation of the TCR α-chain, which 
indirectly contribute to the preferential recognition of some 
antigens or modulate the affinity for antigen/CD1d complexes 
(99–101). For the recognition of β-linked ligands, type I NKT 
TCRs operate through induced-fit molecular mimicry by pushing 
the β-linked headgroup into a flattened position that is similar to 
that of the headgroup of stimulatory α-linked lipids (102–104). 
Therefore, the mode of antigen/CD1d recognition by type I NKT 
TCRs has been compared to the function of pattern-recognition 
receptors that interact in an innate-like and conserved manner 
with ligands that represent microbe-associated molecular pat-
terns or endogenous stress-induced ligands (105, 106).
The Vα24− and Vα10+ NKT TCRs from humans and mice, 
respectively, display very similar conformation compared with 
type I NKT TCRs in complex with α-GalCer/CD1d, except that 
the Vα10+ CDR2α loop is also in contact with the antigen (46) 
and that the Vα24− CDR1α loop interacts with the galactose 
headgroup highly contributing to the TCR fine specificity for the 
antigen (44).
In contrast, structural analysis of the tri-molecular sulfatide/
CD1d/XV19 TCR complex showed that this type II NKT TCR 
docks above the extreme end of the A′ pocket and adopts a parallel 
mode vis-a-vis of the CD1d molecule, similar to the interaction of 
conventional T cell with MHC molecules (Figures 3A,C). Both 
TCR α- and β-chains interact with CD1d and CDR1β and CDR3β 
loops confer recognition and discrimination for the antigen (107, 
108). Unlike the recognition of β-linked glycolipids by the type I 
NKT TCR, the type II NKT TCR does not flatten the sulfatide head-
group during ligation. Thus, differences at the TCR-CD1d/antigen 
interfaces between type I and type II NKT cells provide insights 
into the molecular basis for the different ligand specificities and 
highlight how altered TCR use results in a differing docking solu-
tion on a monomorphic antigen-presenting molecule. The extent 
to which the TCR diversity of type II NKT cells results in different 
docking solutions for distinct TCRs remains to be determined.
Similar to type II NKT TCRs, the TCRs of CD1d-restricted 
γδ T cells dock above the A′ pocket and all CDRδ loops (CDR1δ, 
CDR2δ, CDR3δ) are in contact with CD1d (Figure 3D). Notably, 
the CDR3δ loop also contacts the antigen. Whereas sulfatide 
recognition requires a central position of the δ-chain above the 
lipid portal with no contribution of the TCR γ-chain (77), the 
interaction with α-GalCer involves γ-chain/CD1d contacts and 
a docking mode closer to the extreme end of the A′ pocket (75). 
Thus, γδ T cells can utilize a variety of interactions with their TCR 
γ- and δ-chains to recognize lipid/CD1d complexes.
CD1d Antigen Presentation
In humans, the CD1 family is composed of five isoforms divided 
into two groups: CD1a, CD1b, CD1c, and CD1e forming group 
1 and CD1d forming group 2. In mice, only the CD1d isoform is 
expressed. CD1 molecules are transmembrane glycoproteins that 
display structural similarities to MHC class-I: one heavy chain 
composed of three domains (α1, α2, and α3) non-covalently 
linked to β2-microglobulin via the α3 domain. The CD1d ligand-
binding site is composed of α1 and α2 helices, which form two 
deep hydrophobic pockets, called A′ and F′. The pockets accom-
modate hydrocarbon chains of glycolipid antigens leading to the 
protrusion of the lipid head group on the surface and thus its 
accessibility to the TCR of CD1d-restricted T cells (109, 110). The 
α3 domain connects the ligand-binding region to a transmem-
brane domain, followed by a short cytoplasmic tail. The cytoplas-
mic tail of human and mouse CD1d is critical for its intracellular 
localization as deletion of a tyrosine-based motif encoded in it 
interrupts CD1d recycling between the plasma membrane and 
endolysosomal compartments (Figure 4) (111, 112). Moreover, 
the internalization of murine CD1d and its subsequent lysosomal 
localization require the binding of the adaptor protein complex 
AP-3 to the tyrosine-based motif (113, 114). Interestingly, human 
CD1d fails to bind the AP-3 complex, unlike human CD1b 
(113). In humans, CD1d trafficking from ER to cell surface and 
lysosomes is orchestrated by its physical interaction with MHC 
II and invariant chain (115, 116). By extension from its role in 
CD1d trafficking, the tyrosine-based motif in the cytoplasmic tail 
of CD1d is also critical for type I NKT cell function. Indeed, its 
deletion impaired type I NKT cell development and activation 
by endogenous and exogenous antigens such as α-GalCer (60, 
112, 117). In contrast, CD1d with a truncated cytoplasmic tail is 
still capable of activating type II NKT cells and does not impair 
their development, suggesting that loading of type II NKT cell 
self-antigens onto CD1d occurs within the ER (60, 111, 112). 
Recently, Shin and co-workers have shown that three consecu-
tive arginine residues between the transmembrane region and 
the cytoplasmic tail are involved in the intracellular trafficking 
of CD1d and the presentation of endogenous glycolipids to both 
type I and type II NKT cells (118). Selection and editing of CD1d-
bound lipids is also influenced by accessory lipid-binding and 
-loading molecules such as the microsomal triglyceride transfer 
protein (MTP) and saposins that facilitate the formation of 
lipid/CD1d complexes in the ER and throughout the endocytic 
pathway, respectively (Figure 4). The ability of CD1d molecules 
to differentially stimulate type I versus type II NKT cells based 
on their distinct intracellular trafficking routes is associated with 
FiGURe 3 | Modes of antigen recognition for CD1d-restricted T cell 
receptors. The mode of TCR docking on (A) MHC I or (B–D) CD1d antigen 
complexes. (A) Whereas both TCR α- and β-chain of conventional T cells are in 
contact with the peptide (snaky black line) and the major histocompatibility 
complex class-I (MHC I), (B) the type I NKT cell TCR α-chain interacts with the 
lipid head group of the glycolipid (black circle) that is anchored in the CD1d 
molecule by its acyl chains (black lines), and the β-chain is in contact with the 
CD1d molecule leading to a marked parallel binding position. In an opposite 
manner, the (C) TCR of type II NKT or (D) γδ T cells dock in a perpendicular 
position resulting of the β- or γδ-chains interacting with the polar head group of 
the antigenic lipid. Upper panels: view from the front. Lower panels: view from 
above the TCR.
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loading of distinct self-lipids onto CD1d. Indeed, using lipid 
elution and mass spectrometry, Yuan et  al. demonstrated that 
ER-retained CD1d molecules associated with phosphatidylcho-
line (PC), whereas CD1d molecules that trafficked through the 
secretory pathway were loaded with sphingomyelin for which 
terminal synthesis occurs within the Golgi apparatus (119). 
Interestingly, recycling CD1d molecules carried a combination 
of both sphingomyelin and PC but also lysophospholipids that 
result from lipid degradation by phospholipase in lysosomes. In 
contrast to the presentation of endogenous lipid antigens, activa-
tion of type II NKT cells by exogenous self- or microbial lipids 
requires cellular lipid uptake and intersection of lipid loading 
and intracellular CD1d trafficking in secretory and/or lysosomal 
compartments (93, 120). Thus, different intracellular antigen 
presentation pathways result in formation of stimulatory lipid/
CD1d complexes for type I and type II NKT cells.
Cytokine- and NK Receptor-Mediated Activation
Activation of naïve MHC-restricted T cells is controlled by TCR 
signals that result from highly specific recognition of peptide 
antigen/MHC complexes in combination with receptor-mediated 
co-stimulatory signals, whereas the immediate cytokine milieu is 
critical to guide the differentiation of T cell effector functions. In 
contrast, innate T cells such as type I NKT cells have adopted a 
strategy for their activation that integrates TCR-mediated signal-
ing and stimulation by pro-inflammatory cytokines to result 
in rapid activation (16). Dependent on the context and on the 
affinity of the CD1d-presented lipid antigens, one signal prevails 
over the other. For example, a high-affinity lipid antigen such as 
a potent induced self-lipid or microbial lipid can result in strong 
and predominantly TCR-mediated activation with no or only 
limited need for cytokine stimulation. In contrast, presentation of 
low-affinity microbial or self-antigens requires stimulation with 
antigen-presenting cell-derived inflammatory cytokines to result 
in overt NKT cell activation. This cytokine-mediated stimulation 
can be so strong that it alone results in overt activation, obviating 
the need for TCR-mediated stimulation altogether. This mecha-
nism ensures activation of type I NKT cells early in an ensuing 
inflammatory response during infection even when no microbial 
CD1d-presented lipids are expressed, as is the case, for example, 
during viral infections, and similar mechanisms may explain type 
I NKT cell activation in tumor immunity and autoimmune dis-
eases (121, 122). At steady state, type I NKT cells highly express a 
wide range of cytokine receptors and have therefore the ability to 
respond to multiple cytokines like IL-12 (123, 124), IL-18 (125), 
and IL-23 alone or in combination with IL-1β (126, 127), IL-25 
(30), and IFN type 1 (86). Depending on the cytokines present in 
the inflammatory environment, type I NKT cells secrete different 
cytokines such as IFN-γ in response to IL-12, IL-18 or IFN type 
1, IL-17 with IL-23, and IL-22 with IL-23/IL-1β in combination.
Rolf and co-workers have compared by gene expression pro-
filing the expression of cytokine receptors between type I NKT 
cells and type II NKT cells from 24αβ TCR transgenic mice 
(128). Interestingly, whereas IL-18r1, IL-18rap (IL-18 recep-
tor associated protein), and IL2ra (CD122) were expressed 
at high and similar levels in both subsets, type I NKT cells 
present a higher expression of IL12rb1 (up to 3-fold) and IL2ra 
(CD25) (up to 11-fold). Compared to conventional naïve CD4+ 
FiGURe 4 | Distinct antigen presentation pathways regulate the 
activation of CD1d-restricted T cells. (A) At steady state, endogenous 
lipids are loaded onto CD1d in the endoplasmic reticulum (ER) compartment 
with the help of microsomal triglyceride transfer protein (MTP) and directly 
activate type II NKT cells. Activation of type I NKT cells requires CD1d 
endocytosis and replacement of the bound lipids by antigens present in the 
endosomal compartment, a process that is edited by saposins. (B) 
Inflammation and viral infection lead to alterations of the endogenous lipid 
synthesis and increased expression of secretory phospholipase (sPLA2). This 
results in endogenous phospholipid hydrolysis and generation of stimulatory 
lysophospholipids or enhanced synthesis and/or decreased degradation of 
stimulatory lipids for type I and type II NKT cells, respectively. (C) Pathogenic 
bacteria, fungi, or parasites express microbial lipids that can be loaded onto 
CD1d molecules in endosomal compartments, resulting in the activation of 
type I and II NKT cells. APC, antigen-presenting cell; NKT, natural killer T cell; 
MTP, microsomal triglyceride transfer protein.
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T cells, both type I and type II NKT cells displayed low levels 
of IL1r2, IL6ra, and Ifngr2. Recently, IL-25 has been shown to 
activate type II NKT cells in vivo and promote their produc-
tion of IL-13 through IL17RB (129, 130). This suggests that, 
similar to type I NKT cells, type II NKT cells can respond to 
stimulation with inflammatory cytokines. Interestingly, during 
HBV infection activation of type II NKT cells was primarily 
driven by recognition of CD1d-presented lysophospholipids 
and largely independent of IL-12 signaling, whereas activation 
of type I NKT cells was significantly reduced in the absence 
of IL-12 (53). Whether indirect mechanisms also contribute 
to the activation of CD1d-restricted γδ T cells remains to be 
determined.
Initially named owing to their expression of NK1.1, NKT cells 
express a multitude of both activating (for example, NKG2D, 
NK1.1, CD160, NKR-P1A, NKp46) and inhibitory (Ly49c, 
Ly49G2, NKG2A, 2B4) NK receptors that play an important role 
in their activation and regulation. For example, stimulation of 
NK1.1 and NKG2D was sufficient to directly activate type I NKT 
cells (131, 132), and NKG2D–ligand interactions were critical for 
type II NKT cell-mediated disease induction in a mouse model 
of HBV infection (133). At steady state, both NKT cell subsets 
highly express Klrk1 (NKG2D), Klrb1c (NK1.1), and CD160 but 
only type II NKT cells display high levels of Klra3 (Ly49c), Klra7 
(Ly49G2), and in a lesser manner Ncr1 (NKp46). For their part, 
type I NKT cells express higher levels of Klrb1a (NKR-P1A) and 
Klrc1 (NKG2A) (128).
Thus, in order to overcome the limitations of restricted antigen 
specificity that result from limited TCR diversity and the recogni-
tion of a monomorphic antigen-presenting molecule, both type I 
and type II NKT cells appear able to integrate stimulatory signals 
provided by TCR-mediated stimulation and inflammatory 
cytokines with modulation by NK receptor-signaling, to ensure 
their rapid activation in various infectious and inflammatory 
contexts.
Functions of Type ii NKT Cells
In contrast to the large body of literature previously mentioned 
that has documented a role for type I NKT cells in various 
pathological states, progress in understanding the role of other 
CD1d-restricted T cell populations has been hampered by the 
limited ability to track these cells and the lack of models to assess 
their function in vivo, in particular for Vα24−/Vα14− NKT cells 
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and CD1d-restricted γδ or δ/αβ T cells. However, several lines 
of evidence suggest that type II NKT cells can contribute to and 
modulate a range of immune responses, occasionally in opposing 
roles to type I NKT cells.
Microbial infections
Viral Infections
The first indication that type II NKT cells can contribute to 
protective immunity during viral infection came from studies 
in mice using diabetogenic encephalomyocarditis virus-induced 
pathology (EMCV-D) that is characterized by hind-limb paraly-
sis and impaired glucose-tolerance resulting from virus cytopatic 
effects on neuronal cells and islet cells, respectively. Whereas 
EMCV-D infection resulted in similar disease severity in WT 
and Jα18−/− mice, CD1d−/− mice exhibited a higher incidence 
and exacerbated severity of the disease, suggesting a protective 
role of type II NKT cells during this infection (Figure 5) (134). 
However, this protective function was not unique to type II NKT 
cells since activation of type I NKT cells by α-GalCer provided 
protection of WT mice during EMCV-D infection. An additional 
example of the protective potential of type II NKT cells during 
viral infection comes from studies in humanized SCID mice that 
were infected with HIV-1, in which administration of sulfatide 
resulted in reduced viral replication (135). Thus, natural or 
sulfatide-induced activation of type II NKT cells during viral 
infections can enhance protective innate and adaptive immune 
responses (Figure 5).
Infection with human HBV is a common cause of acute 
and chronic liver injury, including cirrhosis and hepatocellular 
carcinoma. The immune response during HBV infection plays a 
dual role, by eliciting tissue damage in response to viral antigens 
and by controlling viral replication. Mice engineered to express 
HBV envelope proteins in hepatocytes, or a terminally redundant 
HBV DNA construct that results in intrahepatic HBV replication 
has been used to study HBV infection in mice, and showed that 
type II NKT cell responses contributed to acute hepatitis and 
tissue injury in a CD1d- and NKG2D-dependent manner (133, 
136). More recently, Zeissig and colleagues used HBV-expressing 
adenoviral particles to reproduce HBV infection in mice and 
uncovered a protective role for type II NKT cells (53). Type II 
NKT cell activation in response to HBV was dependent on the 
expression of CD1d and MTP (53) which transfers endogenous 
phospholipids onto CD1d (137, 138), suggesting an essential role 
for endogenous lipid presentation. Furthermore, as observed 
both in patients with viral hepatitis and HBV-infected mice, HBV 
infection increased the transcription of the secretory phospho-
lipase A2 (sPLA2) (139) and expression of one of its substrates, 
PE. Interestingly, the analysis of microsomal lipids revealed an 
increase of LPE isoforms able to activate type II NKT cells. Type 
II NKT cell activation during HBV infection was predominantly 
based on LPE recognition, as IL-12 neutralization had little effect. 
By contrast, type I NKT cells did not recognize LPE but required 
IL-12 and MTP, suggesting that their activation occurred after 
type II NKT activation and APC maturation. In addition to their 
critical role in initiating an innate immune response against 
HBV in this model, type II NKT cells appear to also be involved 
in modulating the generation of protective adaptive immune 
responses. Indeed, HBV-infected CD1d−/− mice (lacking both 
type I and type II NKT cells) displayed significantly reduced 
activation of CD4 and CD8 T cells, whereas Jα18−/− mice (lacking 
only type I NKT cells) showed only reduced activation of CD4 
T cells. This type II NKT cell-dependent reduction of adaptive 
CD8+ T cell responses during HBV infection led to a defect in 
viral control and resulted in chronic inflammation (53). Thus, 
in mouse models of HBV infection, type II NKT cells can both 
contribute to immune-mediated tissue damage and to the innate 
and adaptive immune responses that control viral replication 
(Figure  5). In humans, type II NKT cells that produced large 
amounts of IFN-γ, but little IL-13 or IL-4, accumulated in the 
liver during hepatitis C (HCV) infection, but their role during 
infection remains to be determined (140, 141).
Bacterial Infections
As described above, type II NKT cells are activated in response 
to diverse bacterial antigens, suggesting a role for these cells in 
host defense against these bacterial pathogens. During sepsis, the 
immune response consists of a primary phase characterized by a 
potentially lethal cytokine burst induced by activated leukocytes, 
and a secondary latent phase where host defense is reduced. 
Despite the rapid activation of type I NKT cells (increased CD69 
expression, proliferation) after Staphylococcus aureus inocula-
tion, Jα18−/−, CD1d−/−, and WT mice presented comparable 
rates of mortality, suggesting that neither type I nor type II NKT 
cells play a significant protective or deleterious role in S. aureus 
sepsis (142). However, administration of sulfatide concomitant 
with S. aureus inoculation improved the survival rate of mice 
(Figure  5). Interestingly, the protective effect of sulfatide was 
CD1d-dependent and type I NKT cell-independent, suggesting 
that activation of sulfatide-reactive type II NKT cells is essential 
and sufficient for this protective effect. Sulfatide treatment was 
accompanied by a decrease of the inflammatory cytokines TNF-
α and IL-6. Thus, activated sulfatide-reactive type II NKT cells 
reduced the cytokine storm of the primary hyper-reactive phase 
during S. aureus sepsis while maintaining an adequate immune 
response to limit bacterial growth and clearance.
During Mtb infection, type I NKT cells produced IFN-γ 
through stimulation with IL-12/IL-18 and inhibited intracel-
lular bacterial replication by their CD1d-restricted secretion of 
GM-CSF (143, 144). As described above, several type II NKT 
hybridomas were activated by Mtb-infected APC through the 
specific recognition of Mtb phospholipids (93), suggesting that, 
similar to type I NKT cells, type II NKT cells may also contribute 
to protective immunity during Mtb infection. Similarly, given the 
recognition of Lm antigens by type II NKT cells, the increased 
bacterial burden in CD1d−/− during Lm infection as well as the 
ameliorated Lm infection following treatment with blocking anti-
CD1d antibodies suggests that type II NKT cells may contribute 
to protective immunity or have a regulatory function during Lm 
infection (145, 146).
Parasitic Infections
Schistosomiasis is a chronic parasitic disease caused by the 
extracellular parasite Schistosoma, and a strong Th2 response, 
triggered by parasite eggs, is essential for host survival. 
FiGURe 5 | Activation and functions of type ii NKT cells. The stimulation 
by microbial lipids (infection with bacteria or parasites) or self-lipid antigens 
(viral infection, inflammation, or tumor cell) in combination, or not, with 
cytokines, leads to the activation of type II NKT cells. Dependent on the 
context, type II NKT cells promote or suppress immune responses by 
modulating the activation of type I NKT and T cells, granulocytes, and B cell 
antibody responses, and can even impact directly the integrity of tissues, for 
example, by killing epithelial cells. Whereas type II NKT cells can contribute to 
protective immunity during viral and bacterial infection, they can have 
immunomodulatory effects that reduce disease pathology during experimental 
autoimmune encephalomyelitis (EAE), GVHD, inflammatory liver disease, type 1 
diabetes, or parasitic infection. In contrast, type II NKT cells can also have 
deleterious effects during tumor surveillance, colitis, lupus, obesity, and 
parasitic infection.
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CD1d-deficient mice developed a markedly reduced Th2 
response during schistosomiasis (147) indicating an important 
role of CD1d-restricted T cells in the development of a protective 
immune response. Whereas type I and type II NKT cells were not 
essential during the very early phase (1 and 4 weeks) of infection, 
the two subsets played distinct but complementary roles during 
the acute phase (7 and 12 weeks) of infection (148). Indeed, type 
II NKT cells promoted the Th2 response as their lack induced 
a decrease of Th2 cytokines (IL-4, IL-5, and IL-10) and specific 
IgG1 production (Figure 5), a feature also described in alum-
induced humoral immune response (149). On the other hand, 
secretion of IFN-γ by type I NKT cells contributed to the produc-
tion of specific IgG2b, a marker of Th1 responses. Interestingly, 
schistosome egg-sensitized DC activated type I but not type II 
NKT cells and this activation required the presentation of self-
antigen rather than parasite-derived antigens or TLR2/TLR3 
engagement (148). Nonetheless, Magalhaes and co-workers 
have shown that administration of schistosoma-derived LPC or 
cercaria induced secretion of IL-5 and IL-13 (150) dependent 
on TLR2, and lead to the recruitment of eosinophils at the site of 
infection. The cellular source(s) of Th2 cytokines have not been 
investigated in this model, but considering that LPC is a potent 
type II NKT cell antigen, it is likely that these cells are activated 
during infection.
Natural killer T cell subsets also displayed opposing roles 
during infection with Trypanosoma cruzi (151). T. cruzi infection 
causes a chronic inflammatory disease in which the anti-T. cruzi 
immune response that controls the persistent parasites can also 
contribute to the inflammatory tissue damage of the myocardium 
and gastro-intestinal tract that causes Chagas disease. Indeed, 
Jα18−/− mice were more sensitive to infection with T. cruzi com-
pared to WT or CD1d−/− mice as indicated by greater morbidity 
and mortality. The increased susceptibility to infection in the 
absence of type I NKT cells was accompanied by an enhanced 
inflammatory response with infiltrates of activated cells (NK and 
T cells), B cells and DC in lymphoid organs and greater muscle 
inflammation and pro-inflammatory cytokine secretion (IFN-
γ, TNF-α, nitric oxide). Moreover, the humoral response was 
impaired as shown by a decreased anti-T. cruzi IgG2a antibody 
titer, compared to WT and CD1d−/− mice. This suggests that 
during T. cruzi infection, type II NKT cells augment the inflam-
matory anti-parasite response, whereas type I NKT cells limit this 
response (Figure 5).
Together, these examples show that in a range of viral, 
bacterial, and parasitic infections type II NKT cells can either 
promote protective innate and adaptive cell-mediated immune 
responses, or contribute to infection-induced pathology. 
Understanding the mechanisms that determine these opposing 
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functions of type II NKT cells during infection will be important 
areas of future research.
Anti-Tumor immunity
Type I NKT cells critically contribute to natural anti-tumor 
responses, as demonstrated by the prompt growth of spontane-
ous tumors in type I NKT cell-deficient Jα18−/− mice compared to 
WT mice (152–154). Furthermore, the activation of type I NKT 
cells by α-GalCer provides potent effects against hematologic 
malignancies and solid tumors through their IFN-γ-production 
and the subsequent activation of DC and NK cells (155, 156). 
By contrast, sulfatide-activated type II NKT cells repress anti-
tumor immunity (Figure 5) (157–159) by abrogating type I NKT 
activation in response to α-GalCer, in terms of cytokine secre-
tion and expansion (160). Moreover, their IL-13 production, in 
combination with TNF-α, led to up-regulation of TGF-β secre-
tion by myeloid-derived suppressor cells (MDSC), and resulted 
in decreased cytotoxic T cell activity (161). Interestingly, in 
contrast to their notable immunoregulatory role in anti-tumor 
responses, two recent studies have highlighted the ability of type 
II NKT cells to contribute to anti-tumor immunity in response 
to CpG in a B16 melanoma model (54), and by their ability to 
directly kill lymphoma cells in  vitro (63). Thus, type II NKT 
cells can suppress anti-tumor immunity, counteracting the 
anti-tumor activity of type I NKT cells, but can also contribute 
to defense against tumor growth. Understanding the factors 
that determine the role of type II NKT cells in tumor immunity 
will be critical to harness their potential in novel anti-tumor 
strategies.
Autoimmunity and Tolerance
Type II NKT cells help maintain tolerance to self-antigens and 
thereby prevent autoimmune disease. On the other hand, they 
also can mediate tissue damage and play a pathogenic role in 
autoimmunity.
Experimental Autoimmune Encephalomyelitis
An important role for type II NKT cells has been shown in 
experimental autoimmune encephalomyelitis (EAE), a mouse 
model for multiple sclerosis. During EAE, sulfatide-mediated 
activation of type II NKT cells induced tolerogenic DC polari-
zation, abrogated activation of both type I and type II NKT 
cells, class-II MHC effector myelin protein reactive T cells, 
and microglial cells and suppressed autoimmunity (Figure 5) 
(55, 162).
Type 1 Diabetes
NOD mice, which spontaneously develop type 1 diabetes, were 
protected from disease following sulfatide administration that 
led to type II NKT cell activation and secretion of IL-10 by DC, 
resulting in inhibition of type I NKT cells and activation and 
expansion of diabetogenic T cells (Figure 5) (163). In contrast, in 
another study using a different experimental approach, sulfatide 
failed to protect NOD mice from diabetes (164). A non-sulfatide-
reactive type II NKT cell subset was also able to protect NOD 
mice from diabetes by regulating diabetogenic T cells through 
PD-1/PD-L1 and ICOS/ICOSL pathways (66, 165).
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease 
characterized by antinuclear autoantibodies (IgG2a particularly) 
and multiorgan injury such as proteinuria and immune complex 
glomerulonephritis, which is dependent on IFN-γ (166, 167). 
Whereas α-GalCer administration exacerbated the disease by 
inducing a strong Th1 response, CD1d-blocking slowed down 
the development of the disease mediated by a decrease of IgG2a 
production (167). Interestingly, transfer of splenic CD4+, CD8+, 
or DN Vα4.4/Vβ9 type II NKT cells, purified from transgenic 
mice generated with CD1d-reactive T cells initially derived from 
irradiated mice, promoted the disease by producing large amount 
of IFN-γ. By contrast, NKT cells derived from bone marrow and 
displaying a DN phenotype prevented SLE by secreting large 
amounts of IL-4 (166).
Colitis
Type II NKT cells exposed in vivo to high levels of CD1d expres-
sion could directly contribute to the spontaneous development 
of colitis in mice (168). Their harmful role was mediated through 
their IL-13 secretion induced by IL-25 and their cytotoxic activity 
against epithelial cells (Figure 5) (56, 129, 169).
Liver Diseases, GvHD, and Obesity
Halder and co-workers have shown that presentation of sulfa-
tide by hepatic plasmacytoid DC (pDC) to type II NKT cells 
led to the recruitment of anergic type I NKT cells, in a IL-12- 
and MIP-2-dependent manner and prevented concanavalin 
A-induced hepatitis (170). The same group has also shown 
that type II NKT cells neutralized the pathogenic role of type I 
NKT cell during hepatic ischemic reperfusion disease (50) and 
alcoholic liver disease (94). Indeed, activation of type II NKT 
cells after sulfatide administration suppressed IFN-γ produc-
tion by hepatic type I NKT cells and inhibited the recruitment 
of myeloid cells in the liver that have been shown to enhance 
injury (Figure 5) (171).
In bone-marrow (BM) transfer, both host-residual and donor-
derived NKT cells exert protective functions that are particularly 
well described in graft-versus-host disease (GVHD). Whereas 
protection by host-residual T cells was provided by the type 
I NKT subset, type II NKT cells played critical roles in donor-
derived protective effects (172–175). Indeed, on the one hand, 
adoptive transfer of type I NKT cells or the administration of 
α-GalCer attenuated GVHD in recipient mice due to the vigorous 
secretion of IL-4 by type I NKT cells and the subsequent Th2 
polarization of the immune response (172–175). On the other 
hand, donor BM type II NKT cells produced IL-4, like type I NKT 
cells, but also IFN-γ which induced apoptosis of donor CD4+ and 
CD8+ T cells in a Fas-dependent manner (174, 176). Moreover, 
Exley and co-workers have shown that human CD161+ CD1d-
reactive BM-derived non-invariant T cells specifically suppress 
mixed-lymphocytes reaction (MLR) and could induce tolerance 
to allografts (67).
In obesity, activation of type II NKT cells by lipid excess 
initiated adipose tissue and liver inflammation leading to obesity 
(177). By contrast, Hams and colleagues found that type II NKT 
cells activated by IL-25 regulated weight and glucose homeostasis 
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by recruiting to visceral adipose tissue eosinophils and activated 
macrophages that are found in lean individuals (130).
Thus, in a context-dependent manner, type II NKT cells 
provide protective or deleterious effects in a number of diverse 
diseases including microbial infection, anti-tumor immunity, and 
autoimmunity (Figure 5), suggesting that these cells may consti-
tute promising therapeutic targets for a broad range of diseases.
Summary and Future Directions
Significant progress has been made in defining the diversity 
among CD1d-restricted T cells that, in addition to the widely 
studied type I NKT cells, include α-GalCer-reactive NKT cells 
that use non-canonical TCRs, type II NKT cells that use a more 
diverse repertoire of αβ TCRs, as well as T cells that use γδ or 
δ/αβ TCRs. Critical differences distinguish the members of the 
CD1d-restricted T cell family beyond their use of different TCRs, 
including their antigen specificities and modes of antigen/CD1d 
recognition. A major hurdle in unraveling the biology of the 
CD1d-restricted T cell subsets that do not recognize α-GalCer is 
the difficulty to reliably detect and analyze these cells in humans 
and mice ex vivo and in vivo. Discovery of new self- and foreign 
antigens in combination with strategies and tools to directly 
detect these cells such as antigen-loaded CD1d tetramers, and 
availability of suitable small animal models will be necessary to 
characterize the entire repertoire and to determine the degree of 
diversity versus oligoclonality among all CD1d-restricted T cell 
subsets. Furthermore, it is currently unknown to what extent 
the differences in TCR usage and antigen specificity of these 
subsets correlate with phenotypic attributes or immunologic 
functions that are distinct from those of type I NKT cells. For 
example, in anti-tumor immunity and in response to microbial 
infection, type II NKT cells have been shown to have opposing 
functions to those of type I NKT cells. In addition, while many 
non-invariant CD1d-restricted T cells appear to display a type 
I NKT cell-like activated/memory phenotype, several studies 
have indicated that CD1d-restricted T cells exist that are more 
similar to conventional MHC-restricted T cells. Importantly, it 
remains to be determined if truly naïve CD1d-restricted T cells 
exist that can mount antigen-specific memory T cell responses 
following primary stimulation and expansion. Given their 
ability to recognize bacterial antigens including ones expressed 
by Mtb, this would provide a rationale to target these cells in 
vaccine strategies. In analogy to the functionally distinct type 
I NKT cell subsets that comprise NKT1, NKT2, NKT17, and 
NKTFH cells, the Th2-bias observed among some human type 
II NKT cells and following sulfatide administration, and the 
discovery of TFH-like type II NKT cells in humans and mice 
suggest that functionally distinct subsets may also exist among 
non-invariant CD1d-restricted T cells. Correlation of such 
functional differences with antigen specificity would allow 
therapeutic targeting of these cells with activating or inhibitory 
ligands.
Several examples illustrate that non-invariant NKT cells, in 
particular type II NKT cells, critically contribute to the immune 
responses in a wide range of diseases, including microbial infec-
tion, anti-tumor immunity, and autoimmunity. Central to our 
understanding of the varied roles of CD1d-restricted T cells is 
unraveling the mechanisms that regulate their activation in these 
diverse conditions. During infection, recognition of inducible 
self-lipid antigens in combination with stimulation by the inflam-
matory milieu through cytokines, or direct recognition of micro-
bial antigens results in the rapid activation of CD1d-restricted T 
cells. How these T cells distinguish between self- and microbial 
lipids, whether activation by antigens with different affinities 
results in distinct functional outcomes, and whether recognition 
of inducible self-antigens extends to non-infectious conditions 
such as tumor immunity or autoimmunity are currently not 
known. Defining the context-dependent mechanisms of activa-
tion, decrypting the disease-specific balance of protective and 
potentially harmful functions of the different CD1d-restricted T 
cell populations and a better understanding of their effector func-
tions and interactions with other immune cells present significant 
ongoing challenge and will ultimately determine the success of 
targeting CD1d-restricted T cells for preventive or therapeutic 
interventions.
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